In a phase II clinical trial, PJ led to a prolongation of doubling time of rising serum PSA in men with recurrent PCa, consistent with a direct effect of PJ metabolites on PCa cell growth [3]. The gene discussed is PROS1; the disease is posterior cortical atrophy.